Pientzehuang Pharmaceutical's healthcare fund completes regulatory filing

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Pientzehuang Investment, has confirmed the completion of private equity fund filing for the Gaoxin Runxin Greater Healthcare Industry Investment Partnership. The fund has been registered with the Asset Management Association of China, acquiring a Private Investment Fund Filing Certificate.

Pientzehuang Investment is a limited partner in the Gaoxin Runxin Fund, committing an investment of 200 million yuan, representing 20.00% of the fund's capital. This strategic investment aims to bolster the company's integration capabilities across the pharmaceutical industry value chain and enhance its core competitiveness. The fund's manager is CITIC Securities Investment Capital Management Co., Ltd., with China Bank Co., Ltd. serving as the custodian.

The company acknowledges potential risks associated with the investment, including a long investment cycle, low liquidity, and the possibility that the fund may not achieve expected returns due to various factors. Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. will closely monitor the fund's operations and strengthen risk management to protect shareholder interests.